

PRESS RELEASE

Lund, Sweden, December 12, 2023

Rights issue in Spago Nanomedical partially registered

The rights issue in Spago Nanomedical AB (publ) (“Spago Nanomedical” or the “Company”) has been registered today and trading in paid subscribed units (“BTU”) will end on 15 December 2023. Due to regulatory reasons, certain guarantors are prevented to receive shares in the rights issue without first obtaining approval from the Inspectorate for Strategic Products (“ISP”). The company has therefore postponed the delivery and final registration of a total of 30,913,334 shares and 30,913,334 warrants, respectively, until the required approvals have been obtained, which is expected to take place in early 2024.

The rights issue that was resolved by the general meeting on 31 October 2023 has today been registered with the Swedish Companies Registration Office and the last day for trading in BTU is 15 December 2023. The cut-off date is 19 December 2023, after which shares and warrants will be booked on the respective shareholders' VP account/deposit on 21 December 2023.

As a result of the entry into force of the Law (2023:560) on the review of foreign direct investment, Spago Nanomedical has postponed the delivery and final registration of a total of 30,913,334 shares and 30,913,334 warrants respectively to certain underwriters in the rights issue until the necessary approvals have been obtained from the ISP, which is expected in early 2024.

The foregoing means that the number of shares and the share capital in Spago Nanomedical now amounts to 187,351,601 shares and SEK 18,735,160.10 respectively, but that the number of shares and the share capital will amount to 218,264,935 shares and SEK 21,826,493.50 respectively when the final registration is complete.

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish company in clinical development phase. The company's development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical's share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the company.

Rights issue in Spago Nanomedical partially registered